Dr. Reardon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Avenue, G460f
Center For Neuro-Oncology, Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-632-6172Fax+1 617-632-4773
Education & Training
- University of MichiganFellowship, Pediatric Hematology/Oncology, 1990 - 1993
- Johns Hopkins UniversityResidency, Pediatrics, 1987 - 1989
- Tufts University School of MedicineClass of 1986
Certifications & Licensure
- FL State Medical License 2022 - Present
- CT State Medical License 2022 - 2025
- MA State Medical License 2011 - 2025
- NC State Medical License 2000 - 2011
- ME State Medical License Active through 2000
- TN State Medical License 1995 - 2000
- MI State Medical License 1989 - 1998
Clinical Trials
- Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Start of enrollment: 2004 Oct 13
- Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) Start of enrollment: 2004 Jan 01
- Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma Start of enrollment: 2004 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 2653 citationsUpdated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupPatrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen
Journal of Clinical Oncology. 2010-04-10 - 696 citationsCilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicen...Roger Stupp, Monika E. Hegi, Thierry Gorlia, Sara Erridge, James Perry
The Lancet. Oncology. 2014-09-01 - 205 citationsPhase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.Michael Lim, Michael Weller, Ahmed Idbaih, Joachim Steinbach, Gaetano Finocchiaro
Neuro-Oncology. 2022-11-02
Journal Articles
- Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with GlioblastomaDavid Reardon, MD, JAMA Oncology
- Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with GlioblastomaDavid Reardon, MD, JAMA Oncology
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaDavid A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
Authored Content
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Press Mentions
- In Mouse Study, New Gel Therapy Stops Dangerous Brain TumorsApril 26th, 2023
- Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory BoardMarch 21st, 2022
- A Revolutionary Clinical Trial Is Testing Customized Vaccines That Target Cancerous TumorsNovember 4th, 2021
- Join now to see all
Grant Support
- Translational Clinical Trials For Primary CNS TumorsNational Institute Of Neurological Disorders And Stroke2009–2012
- Core--Phase I/II Clinical TrialsNational Cancer Institute2007–2008
- Translational Clinical Trials In Neuro-OncologyNational Institute Of Neurological Disorders And Stroke2004–2008
- Core-3-Phase I/II Clinical TrialsNational Cancer Institute2004–2006
- Phase II Study Of 44gy From 131i-81c6 For CNS TumorsNational Cancer Institute2003–2004
- Core--Phase I / II Clinical Trials CoreNational Cancer Institute2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: